Mount Sinai Leading a Clinical Trial Evaluating Allogeneic Stem Cell Therapy on COVID-19 ARDS Patients

Mount Sinai Leading a Clinical Trial Evaluating Allogeneic Stem Cell Therapy on COVID-19 ARDS Patients

Mount Sinai Health System will be conducting a study using remestemcel-L (Ryoncil), an innovative allogeneic stem cell therapy in patients with coronavirus disease 2019 (COVID-19). Mount Sinai will play a central role in a clinical trial for patients with severe acute respiratory distress syndrome, which affects individuals with severe cases of COVID-19.

What is Remestemcel-L?

Consisting of mesenchymal stem cells, this therapy has been previously assessing for other indications such as in a Phase III study involving children who had graft-versus-host disease (GVHD)—these can happen after bone marrow transplants. Of relevance for the recent COVID-19 pandemic, the inflammation involved with GVHD can result from a cytokine storm—the same phenomenon that can occur with COVID-19 patients when developing acute respiratory distress syndrome (ARDS).

TrialSite News recently discussed the FDA’s greenlight of Mesoblast’s Investigational New Drug (IND) application for Remestemcel-L. The sponsor could now commence with  clinical trials addressing acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2 infection with intravenous infusions of its allogeneic mesenchymal stem cell...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee